CHRNA7 polymorphisms and response to cholinesterase inhibitors in Alzheimer's disease

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Weng, Pei Hsuan ^a,b   Chen, Jen Hau ^b,c   Chen, Ta Fu ^c   Sun, Yu ^d   Wen, Li Li ^d   Yip, Ping Keung ^e,f   Chu, Yi Min ^e   Chen, Yen Ching ^b  

^a TAIWAN ADVENTIST HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d EN CHU KONG HOSPITAL   (Taiwan)

^e CARDINAL TIEN HOSPITAL   (Taiwan)

^f FU JEN CATHOLIC UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 84894214006     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0084059     Document Type: Article

References (47)

1. Coyle JT, Price DL, DeLong MR (1983) Alzheimer's disease: a disorder of cortical cholinergic innervation. Science 219: 1184-1190. (Pubitemid 13160659)
2. London ED, Ball MJ, Waller SB (1989) Nicotinic binding sites in cerebral cortex and hippocampus in Alzheimer's dementia. Neurochem Res 14: 745-750. (Pubitemid 19255829)
3. Taylor P (1998) Development of acetylcholinesterase inhibitors in the therapy of Alzheimer's disease. Neurology 51: S30-35; discussion S65-37.
4. Lam B, Hollingdrake E, Kennedy JL, Black SE, Masellis M (2009) Cholinesterase inhibitors in Alzheimer's disease and Lewy body spectrum disorders: the emerging pharmacogenetic story. Hum Genomics 4: 91-106.
5. O'Brien KK, Saxby BK, Ballard CG, Grace J, Harrington F, et al. (2003) Regulation of attention and response to therapy in dementia by butyrylcholinesterase. Pharmacogenetics 13: 231-239. (Pubitemid 36543396)
6. Blesa R, Bullock R, He Y, Bergman H, Gambina G, et al. (2006) Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease. Pharmacogenet Genomics 16: 771-774. (Pubitemid 44632290)
7. Patterson CE, Todd SA, Passmore AP (2011) Effect of apolipoprotein E and butyrylcholinesterase genotypes on cognitive response to cholinesterase inhibitor treatment at different stages of Alzheimer's disease. Pharmacogenomics J 11: 444-450.
8. Scacchi R, Gambina G, Moretto G, Corbo RM (2009) Variability of AChE, BChE, and ChAT genes in the late-onset form of Alzheimer's disease and relationships with response to treatment with Donepezil and Rivastigmine. Am J Med Genet B Neuropsychiatr Genet 150B: 502-507.
9. Harold D, Macgregor S, Patterson CE, Hollingworth P, Moore P, et al. (2006) A single nucleotide polymorphism in CHAT influences response to acetylcholinesterase inhibitors in Alzheimer's disease. Pharmacogenet Genomics 16: 75-77. (Pubitemid 43145675)
10. Chianella C, Gragnaniello D, Maisano Delser P, Visentini MF, Sette E, et al. (2011) BCHE and CYP2D6 genetic variation in Alzheimer's disease patients treated with cholinesterase inhibitors. Eur J Clin Pharmacol 67: 1147-1157.
11. Noetzli M, Eap CB (2013) Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease. Clin Pharmacokinet 52: 225-241.
12. Pilotto A, Franceschi M, D'Onofrio G, Bizzarro A, Mangialasche F, et al. (2009) Effect of a CYP2D6 polymorphism on the efficacy of donepezil in patients with Alzheimer disease. Neurology 73: 761-767.
13. Cacabelos R (2008) Pharmacogenomics and therapeutic prospects in dementia. Eur Arch Psychiatry Clin Neurosci 258 Suppl 1: 28-47.
14. Mannens GS, Snel CA, Hendrickx J, Verhaeghe T, Le Jeune L, et al. (2002) The metabolism and excretion of galantamine in rats, dogs, and humans. Drug Metab Dispos 30: 553-563. (Pubitemid 34456978)
15. Martinelli-Boneschi F, Giacalone G, Magnani G, Biella G, Coppi E, et al. (2013) Pharmacogenomics in Alzheimer's disease: a genome-wide association study of response to cholinesterase inhibitors. Neurobiol Aging 34: 1711 e1717-1713.
16. Murcray CE, Lewinger JP, Gauderman WJ (2009) Gene-environment interaction in genome-wide association studies. Am J Epidemiol 169: 219-226.
17. Carson R, Craig D, McGuinness B, Johnston JA, O'Neill FA, et al. (2008) Alpha7 nicotinic acetylcholine receptor gene and reduced risk of Alzheimer's disease. J Med Genet 45: 244-248. (Pubitemid 351518731)
18. Barabash A, Marcos A, Ancin I, Vazquez-Alvarez B, de Ugarte C, et al. (2009) APOE, ACT and CHRNA7 genes in the conversion from amnestic mild cognitive impairment to Alzheimer's disease. Neurobiol Aging 30: 1254-1264.
19. Frazier CJ, Buhler AV, Weiner JL, Dunwiddie TV (1998) Synaptic potentials mediated via alpha-bungarotoxin-sensitive nicotinic acetylcholine receptors in rat hippocampal interneurons. J Neurosci 18: 8228-8235. (Pubitemid 28465000)
20. Albuquerque EX, Santos MD, Alkondon M, Pereira EF, Maelicke A (2001) Modulation of nicotinic receptor activity in the central nervous system: a novel approach to the treatment of Alzheimer disease. Alzheimer Dis Assoc Disord 15 Suppl 1: S19-25.
21. Texido L, Ros E, Martin-Satue M, Lopez S, Aleu J, et al. (2005) Effect of galantamine on the human alpha7 neuronal nicotinic acetylcholine receptor, the Torpedo nicotinic acetylcholine receptor and spontaneous cholinergic synaptic activity. Br J Pharmacol 145: 672-678. (Pubitemid 41032639)
22. Mitsushima D (2010) Sex steroids and acetylcholine release in the hippocampus. Vitam Horm 82: 263-277.
23. Rhodes ME, Rubin RT (1999) Functional sex differences ('sexual diergism') of central nervous system cholinergic systems, vasopressin, and hypothalamic-pituitary-adrenal axis activity in mammals: a selective review. Brain Res Brain Res Rev 30: 135-152. (Pubitemid 29440937)
24. Koylu E, Demirgoren S, London ED, Pogun S (1997) Sex difference in upregulation of nicotinic acetylcholine receptors in rat brain. Life Sci 61: PL 185-190.
25. Luine VN, Renner KJ, Heady S, Jones KJ (1986) Age and sex-dependent decreases in ChAT in basal forebrain nuclei. Neurobiol Aging 7: 193-198. (Pubitemid 16021590)
26. Lin KP, Chen SY, Lai LC, Huang YL, Chen JH, et al. (2011) Genetic polymorphisms of a novel vascular susceptibility gene, Ninjurin2 (NINJ2), are associated with a decreased risk of Alzheimer's disease. PLoS One 6: e20573.
27. McKhann G, Drachman D, Folstein M, Katzman R, Price D, et al. (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34: 939-944. (Pubitemid 14076461)
28. Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-198.
29. Katzman R, Zhang MY, Ouang Ya Q, Wang ZY, Liu WT, et al. (1988) A Chinese version of the Mini-Mental State Examination; impact of illiteracy in a Shanghai dementia survey. J Clin Epidemiol 41: 971-978. (Pubitemid 19002065)
30. US Food and Drug Administration. Peripheral and central nervous system drugs advisory committee meeting. Rockville (MD): Department of Health and Human Services, Public Health Service, 1989: 227.
31. Doraiswamy PM, Bieber F, Kaiser L, Krishnan KR, Reuning-Scherer J, et al. (1997) The Alzheimer's Disease Assessment Scale: patterns and predictors of baseline cognitive performance in multicenter Alzheimer's disease trials. Neurology 48: 1511-1517.
32. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, et al. (2002) The structure of haplotype blocks in the human genome. Science 296: 2225-2229. (Pubitemid 34680308)
33. Chen YC, Giovannucci E, Lazarus R, Kraft P, Ketkar S, et al. (2005) Sequence variants of Toll-like receptor 4 and susceptibility to prostate cancer. Cancer Res 65: 11771-11778. (Pubitemid 41821739)
34. Stram DO, Leigh Pearce C, Bretsky P, Freedman M, Hirschhorn JN, et al. (2003) Modeling and E-M estimation of haplotype-specific relative risks from genotype data for a case-control study of unrelated individuals. Hum Hered 55: 179-190. (Pubitemid 37323455)
35. Chapman J, Estupinan J, Asherov A, Goldfarb LG (1996) A simple and efficient method for apolipoprotein E genotype determination. Neurology 46: 1484-1485. (Pubitemid 26159322)
36. Calabria M, Geroldi C, Lussignoli G, Sabbatini F, Zanetti O (2009) Efficacy of acetyl-cholinesterase-inhibitor (ACHEI) treatment in Alzheimer's disease: a 21-month follow-up "real world" study. Arch Gerontol Geriatr 49: e6-11.
37. Kumar V, Anand R, Messina J, Hartman R, Veach J (2000) An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors. Eur J Neurol 7: 159-169. (Pubitemid 32260563)
38. Poirier J, Delisle MC, Quirion R, Aubert I, Farlow M, et al. (1995) Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc Natl Acad Sci USA 92: 12260-12264. (Pubitemid 26014050)
39. Benjamini Y, Hochberg Y (1995) Controlling the False Discovery Rate - a Practical and Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society Series B-Methodological 57: 289-300.
40. Mehta CR, Patel NR (1995) Exact logistic regression: theory and examples. Stat Med 14: 2143-2160.
41. Barash Y, Calarco JA, Gao W, Pan Q, Wang X, et al. (2010) Deciphering the splicing code. Nature 465: 53-59.
42. Liao PY, Lee KH (2010) From SNPs to functional polymorphism: The insight into biotechnology applications. Biochemical Engineering Journal 49: 149-158.
43. Takada-Takatori Y, Kume T, Sugimoto M, Katsuki H, Sugimoto H, et al. (2006) Acetylcholinesterase inhibitors used in treatment of Alzheimer's disease prevent glutamate neurotoxicity via nicotinic acetylcholine receptors and phosphatidylinositol 3-kinase cascade. Neuropharmacology 51: 474-486. (Pubitemid 44215955)
44. Akaike A, Takada-Takatori Y, Kume T, Izumi Y (2010) Mechanisms of neuroprotective effects of nicotine and acetylcholinesterase inhibitors: role of alpha4 and alpha7 receptors in neuroprotection. J Mol Neurosci 40: 211-216.
45. Wonnacott S, Barik J, Dickinson J, Jones IW (2006) Nicotinic receptors modulate transmitter cross talk in the CNS: nicotinic modulation of transmitters. J Mol Neurosci 30: 137-140. (Pubitemid 46035352)
46. Kume T, Sugimoto M, Takada Y, Yamaguchi T, Yonezawa A, et al. (2005) Upregulation of nicotinic acetylcholine receptors by central-type acetylcholinesterase inhibitors in rat cortical neurons. Eur J Pharmacol 527: 77-85. (Pubitemid 41745154)
47. Geerts H, Guillaumat PO, Grantham C, Bode W, Anciaux K, et al. (2005) Brain levels and acetylcholinesterase inhibition with galantamine and donepezil in rats, mice, and rabbits. Brain Res 1033: 186-193. (Pubitemid 40193413)